Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 620 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buprenorphine Clear all
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2010 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study

NCT01151098
View directory record Official record
Conditions
Chronic Nonmalignant Pain
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
19
States / cities
Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
View directory record Official record
Conditions
Depression
Interventions
0.2mg Buprenorphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence

NCT02496403
View directory record Official record
Conditions
Opiate Substitution Treatment
Interventions
Standard Medical Management (SMM)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Integrated Treatment for Pain and Opioid Dependence

NCT00634803
View directory record Official record
Conditions
Opiate Dependence, Chronic Pain
Interventions
CBT, Buprenorphine, Educational Counseling, Physician Management
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 19, 2026, 10:17 AM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 19, 2026, 10:17 AM EDT
Recruiting Not applicable Interventional

Personalized Addiction Treatment enHancement

NCT07778394
View directory record Official record
Conditions
Opioid Use Disorder, mHealth, Peer Support
Interventions
Vira Platform, Treatment-As-Usual
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial

NCT00684554
View directory record Official record
Conditions
Opioid-Related Disorders, Heroin Dependence
Interventions
Buprenorphine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 19, 2026, 10:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine / Naloxone
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

NCT01738503
View directory record Official record
Conditions
Opioid Related Disorder
Interventions
RBP-6000, Subutex
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Hydromorphone on Responses to Verbal Tasks

NCT02205983
View directory record Official record
Conditions
Healthy
Interventions
2 mg hydromorphone, 1000 mg Acetaminophen, 4 mg hydromorphone, dextrose
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Pilot Test of a Community-based Buprenorphine Treatment Intervention

NCT01761110
View directory record Official record
Conditions
Opioid Dependence, Injection Drug Use
Interventions
Community-based buprenorphine treatment (CBBT) intervention
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Examine Plasma Concentrations of Buprenorphine Following Reapplication of Buprenorphine Transdermal System (BTDS) After Variable Application Site Rest Periods

NCT01259102
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 4 Interventional

Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

NCT00798538
View directory record Official record
Conditions
Buprenorphine, HIV, Drug Abuse, Drug Addiction, Drug Dependence, Drug Use Disorders, Drug Use Disorder, Substance Abuse, Opiate Addiction, Substance-related Disorders
Interventions
Services will be provided at one site, Services remain dispersed; i.e., not centralized to one-location or provider.
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 19, 2026, 10:17 AM EDT
Withdrawn Phase 2 Interventional

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1

NCT00000326
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Analgesia After Total Shoulder Arthroplasty

NCT01782872
View directory record Official record
Conditions
Total Shoulder Arthroplasty
Interventions
Interscalene Block (ISB) - 0.375% Ropivacaine + additives, Interscalene Block (ISB) - 0.2% Ropivacaine + additives, Interscalene Block (ISB) - 0.1% Ropivacaine + additives, Interscalene Block (ISB) - Systemic Control
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 3 Interventional

Re-Treatment Study of Probuphine in Opioid Addiction

NCT01262261
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 2 Interventional

Medical Office Intervention for Adolescent Drug Use

NCT00229983
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Motivational Enhancement Therapy
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

Buprenorphine Dose Alteration Study - 1

NCT00000219
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
University of Vermont
Other
Eligibility
19 Years to 41 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2001
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 19, 2026, 10:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Innovatively Increasing PCP Prescribing of Buprenorphine: Measurement Based Care and Integrated Electronic Solution

NCT04059016
View directory record Official record
Conditions
Opioid Abuse and Addiction
Interventions
MBC4OUD
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 19, 2026, 10:17 AM EDT
Recruiting Phase 2 Interventional

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06067737
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 19, 2026, 10:17 AM EDT
Recruiting No phase listed Observational

EMS-Initiated Buprenorphine

NCT07475728
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Oakland, California • Minneapolis, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 10:17 AM EDT
Completed Not applicable Interventional

tAN for PTSD and OUD in Buprenorphine Therapy

NCT06130501
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Opioid Use Disorder
Interventions
Sparrow Ascent tAN, Sparrow Ascent Active Sham
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cape Girardeau, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 10:17 AM EDT
Terminated Phase 2 Interventional Results available

Monthly Injectable BUP for MA Use Disorder (MURB) Trial

NCT05283304
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Buprenorphine injection (BUP-Inj), Placebo injection
Drug · Other
Lead sponsor
Madhukar H. Trivedi, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Tulsa, Oklahoma + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 19, 2026, 10:17 AM EDT